Prime Minister's Intervention On Patents And Data Protection Issue Sparks Fresh Row Between Indian And Multinational Drug Makers
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Leading multinational and India drug companies are heading for a veritable face-off over a decision of the prime minister's office to step in for a comprehensive legislative review of contentious statutes related to patent law in India